Key result
Among 165 consecutive patients, implantation of the SAPIEN 3 transcatheter heart valve resulted in none or trace paravalvular leak in 89.7%, with no cases of moderate or severe leak.
Why the study?
Does the Edwards SAPIEN 3 transcatheter heart valve reduce paravalvular leak compared to previous generation valves?
Observational (n=165)
Does the Edwards SAPIEN 3 transcatheter heart valve reduce paravalvular leak compared to previous generation valves?
The SAPIEN 3 transcatheter heart valve, with its outer skirt design, requires less oversizing and results in very low rates of moderate or severe paravalvular leak.
Technique adjustments for SAPIEN 3 may reduce PVL; leaves open prospective validation of optimal deployment.
The new balloon-expandable Edwards SAPIEN 3 THV has significant design improvements requiring adjustments in the implantation technique as compared to the previous generation SAPIEN XT. Basically, the new valve requires less oversizing due to the outer skirt, which, if positioned underneath the annulus, can reduce the occurrence and severity of paravalvular leak (PVL). As with any transcatheter vale, a thorough assessment of the device-landing-zone, the surrounding structures, and the distribution of calcifications is of vast importance. Once the SAPIEN 3 valve is positioned with the initial orientation of the middle balloon marker at the level of the leaflet hinge points, the outer skirt will remain under the annulus, despite the foreshortening of the lower inflow portion of the valve. If there is an incomplete apposition, the outer skirt can conform to the anatomy, close the gaps, and reduce the risk of PVL. When calcifications are located on the edges of the annulus, PVL is common with the SAPIEN XT THV but dramatically reduced with the SAPIEN 3 THV. If the calcification extends from the annulus into the entire LVOT, there is always an incomplete apposition of the either valve frame; however, the resulting PVL is reduced by the outer skirt of the SAPIEN 3. In 165 consecutive SAPIEN 3 patients, 89.7% (n = 145) had none or a trace PVL and there were no patients with moderate or severe PVL. The new generation SAPIEN 3 valve allows more challenging anatomies to be treated, requires less oversizing, and can reduce PVL.
No takes yet. Share an insight, caveat, or question.
Schymik et al. (2014) conducted an observational in Transcatheter heart valve implantation (n=165). SAPIEN 3 Transcatheter Heart Valve was evaluated on None or trace paravalvular leak (PVL). Among 165 consecutive patients, implantation of the SAPIEN 3 transcatheter heart valve resulted in none or trace paravalvular leak in 89.7%, with no cases of moderate or severe leak.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: